Surrozen, Inc.
Regulated industryPhysical productsSells to businessesDevelopment stageTags from an AI model reading the company description.
Key Metrics
- Previous Close
- $30.67
- 52-Week Range
- $12.79 – $37.83
- Market Cap
- $596.41M
- P/E (TTM)
- —
- EPS (TTM)
- -38.95
- Dividend Yield
- 0.00%
Advanced Metrics
- Price/Book
- —
- PEG Ratio
- —
- Return on Equity
- —
- Return on Assets
- -31.46%
- Gross Margin
- -257.52%
- Operating Margin
- -485.44%
- Profit Margin
- 0.00%
- Current Ratio
- 7.56
- Debt/Equity
- —
- Total Debt
- $5.84M
- Free Cash Flow
- $-14.76M
- Revenue Growth
- —
- Earnings Growth
- —
- Enterprise Value
- $447.98M
Market Snapshot
About
Surrozen, Inc. is a clinical-stage biotechnology company discovering and developing drug candidates to selectively modulate the Wnt pathway. The companys antibody-based therapeutics target tissue-specific disease processes across multiple organs including the eye, liver, intestine, and kidney. It aims to address diseases where Wnt pathway dysregulation plays a critical role.